Recent studies have described the role of melatonin as a sleep regulator and as an anti- oxidative neuroprotective agent in improving sleep quality and delaying cognitive decline in Alzheimer's disease (AD). In accordance with this data, our hypothesis is that melatonin will delay the cognitive decline in Mild Cognitive Impairment (MCI) patients and reduce the conversion rate from MCI to AD.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
50
5 mg, oral, daily dose for 6 months
Memory clinic, 'Asaf Harofeh' medical center
Ẕerifin, Israel
RECRUITINGa delay in cognitive decline as measured by memory tests
Time frame: 6 months
Reduced MCI conversion rate to AD per year
Time frame: Two years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.